AstraZeneca announced positive high-level data from the HIMALAYA Phase III trial of a single, high priming dose of tremelimumab plus Imfinzi (durvalumab) in patients with unresectable hepatocellular carcinoma (HCC), or liver cancer, who had not had previous systemic therapy and were not eligible for localized treatment.
The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee did not agree in a meeting to maintain the accelerated approval of Bristol Myers Squibb’s Opdivo (nivolumab) as a second-line treatment of hepatocellular carcinoma.
Shares of uniQure NV climbed after the company announced the clinical hold on its hemophilia B gene therapy was lifted by the U.S. Food and Drug Administration.
Eisai and Merck agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor.
Eisai Co. Ltd. announced that the results of a Phase III study of its in-house discovered and developed anticancer agent lenvatinib mesylate in patients with hepatocellular carcinoma were published in the online version of The Lancet.
Cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival at the planned second interim analysis for the population of second-line and third-line patients enrolled in the CELESTIAL study.
Shares of Onxeo were down more than 50 percent after the company’s Phase III liver cancer drug Livatag failed to improve survivability over standard of care.
The U.S. FDA accepted a supplemental BLA that seeks to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma after prior sorafenib therapy.
March 1, 2016By Mark Terry, BioSpace.com Breaking News Staff South San Francisco-based Exelixis, Inc. (EXEL) and Paris-based Ipsen (IPN.PA) announced yesterday that they had inked an exclusive licensing agreement […]